Genmab A/S Expects Its 2023 Operating Profit To Be In The Range Of DKK 4,800M – DKK 5,750M, Compared To The Previous Guidance Of DKK 4,500M – DKK 6,000M; Updated 2023 Rev Guidance Driven By Higher Total Royalty Revenues From Darzalex And Other Products
Portfolio Pulse from Benzinga Newsdesk
Genmab A/S has updated its 2023 operating profit guidance to be in the range of DKK 4,800M – DKK 5,750M, compared to the previous guidance of DKK 4,500M – DKK 6,000M. The updated guidance is driven by higher total royalty revenues from Darzalex and other products.
November 07, 2023 | 4:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genmab A/S has updated its 2023 operating profit guidance, which is driven by higher total royalty revenues from Darzalex and other products.
The updated guidance indicates that Genmab A/S expects higher total royalty revenues from Darzalex and other products. This could potentially lead to an increase in the company's stock price in the short term as it indicates a positive financial outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100